Literature DB >> 3281995

Analysis of morbid events and risk factors for death after cardiac transplantation.

J K Kirklin1, D C Naftel, D C McGiffin, R F McVay, E H Blackstone, R B Karp.   

Abstract

Risk factors for death after cardiac transplantation performed at the University of Alabama at Birmingham from January 1981 to July 1985 included (by multivariate analysis) higher calculated preoperative pulmonary vascular resistance (early and constant phases), morphology of cardiomyopathy (versus ischemic heart disease) (constant phase only) and black race (constant phase). Overall actuarial survival was 71% at 1 year and 48% at 3 years (including azathioprine and cyclosporine eras). The hazard function for death was highest immediately after operation and declined rapidly thereafter, merging with a constant phase of risk at about 3 months. The most favorable group for long-term survival was the group of white patients with ischemic heart disease and low pulmonary vascular resistance. When such patients had a pulmonary vascular resistance less than 3 units.m2, the 3 year survival rate exceeded 85%. The most common causes of death were acute rejection (24%) and infection (17%). The risk of infection remained highest during the first several months after any period of augmented immunosuppression.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3281995     DOI: 10.1016/s0735-1097(98)90045-6

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  9 in total

1.  Coronary revascularization rather than cardiac transplantation for chronic ischemic cardiomyopathy.

Authors:  I L Kron; T L Flanagan; L H Blackbourne; R A Schroeder; S P Nolan
Journal:  Ann Surg       Date:  1989-09       Impact factor: 12.969

Review 2.  The challenge of rejection and cardiac allograft vasculopathy.

Authors:  W G Cotts; M R Johnson
Journal:  Heart Fail Rev       Date:  2001-09       Impact factor: 4.214

Review 3.  Myocardial revascularization as a therapeutic strategy in the patient with advanced ventricular dysfunction.

Authors:  F A Mitropoulos; J A Elefteriades
Journal:  Heart Fail Rev       Date:  2001-09       Impact factor: 4.214

Review 4.  [Therapy of terminal heart failure using heart transplantation].

Authors:  M Hummel; H Warnecke; S Schüler; B Hempel; S Spiegelsberger; R Hetzer
Journal:  Klin Wochenschr       Date:  1991-08-16

5.  Mechanisms of transplant right ventricular dysfunction.

Authors:  P Van Trigt; H B Bittner; S W Kendall; C A Milano
Journal:  Ann Surg       Date:  1995-06       Impact factor: 12.969

6.  Fall in pulmonary vascular resistance in patients awaiting heart transplantation.

Authors:  S C Grant; R D Levy; N H Brooks
Journal:  Br Heart J       Date:  1992-10

Review 7.  Heart transplantation in biventricular congenital heart disease: indications, techniques, and outcomes.

Authors:  Bassem N Mora; Charles B Huddleston
Journal:  Curr Cardiol Rev       Date:  2011-05

8.  Tailored total lymphoid irradiation in heart transplant patients: 10-years experience of one center.

Authors:  Pirus Ghadjar; Daniela Joos; Michele Martinelli; Roger Hullin; Marcel Zwahlen; Kristina Lössl; Thierry Carrel; Daniel M Aebersold; Paul Mohacsi
Journal:  Radiat Oncol       Date:  2010-01-16       Impact factor: 3.481

9.  Impact of animal strain on gene expression in a rat model of acute cardiac rejection.

Authors:  Katherine J Deans; Peter C Minneci; Hao Chen; Steven J Kern; Carolea Logun; Sara Alsaaty; Kelly J Norsworthy; Stephanie M Theel; Joel D Sennesh; Jennifer J Barb; Peter J Munson; Robert L Danner; Michael A Solomon
Journal:  BMC Genomics       Date:  2009-06-24       Impact factor: 3.969

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.